Tenax Therapeutics, Inc. (TENX)
| Market Cap | 104.83M -66.5% |
| Revenue (ttm) | n/a |
| Net Income | -64.86M |
| EPS | -1.47 |
| Shares Out | 57.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 789,175 |
| Open | 1.880 |
| Previous Close | 1.870 |
| Day's Range | 1.830 - 1.880 |
| 52-Week Range | 1.310 - 19.400 |
| Beta | 0.92 |
| Analysts | Buy |
| Price Target | 12.56 (+586.34%) |
| Est. Earnings | Nov 11, 2026 |
About TENX
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and ch... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for TENX stock is "Buy." The 12-month stock price target is $12.56, which is an increase of 586.34% from the latest price.
News
Tenax Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Recent trial data showed missed primary endpoint but strong biological effects, especially in sicker patients, with significant NT-proBNP and pressure reductions. Future trials will focus on enrolling less healthy patients to better demonstrate efficacy, with protocol adjustments and positive feedback from experts.
Tenax Therapeutics Slides: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Tenax Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief ...
Guggenheim downgrades Tenax Therapeutics on clinical, regulatory uncertainty
As previously reported, Guggenheim downgraded Tenax Therapeutics (TENX) to Neutral from Buy with no price target While the LEVEL trial presentation at ESC indicated there may be a potential path…
Tenax Therapeutics downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded Tenax Therapeutics (TENX) to Neutral from Buy.
Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103
Tenax Therapeutics (TENX) announced that additional results from the Phase 3 LEVEL clinical trial evaluating TNX-103 in patients with pulmonary hypertension due to heart failure with preserved ejectio...
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $TENX--TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law.
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics
Tenax Therapeutics stock lost approximately 84% to 85% of its value in a single trading session after the Phase 3 LEVEL topline readout. SueWallSt notifies investors of a pending investigation into on...
Tenax Therapeutics downgraded to Neutral from Buy at Chardan
Chardan downgraded Tenax Therapeutics (TENX) to Neutral from Buy with a $5 price target down from $27, after the company announced that the LEVEL Phase III study missed its primary…
Tenax Therapeutics price target lowered to $4 from $35 at Canaccord
Canaccord lowered the firm’s price target on Tenax Therapeutics (TENX) to $4 from $35 and keeps a Buy rating on the shares. The firm noted the company reported that the…
Tenax Therapeutics price target lowered to $4 from $40 at Guggenheim
Guggenheim lowered the firm’s price target on Tenax Therapeutics (TENX) to $4 from $40 and keeps a Buy rating on the shares after the Phase 3 LEVEL trial of oral…
Tenax Therapeutics price target lowered to $4 from $26 at Leerink
Leerink lowered the firm’s price target on Tenax Therapeutics (TENX) to $4 from $26 and keeps an Outperform rating on the shares.
Tenax Therapeutics downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner downgraded Tenax Therapeutics (TENX) to In Line from Outperform with a price target of $5, down from $39, after the LEVEL trail failed in the…
Tenax Therapeutics downgraded to Market Perform from Outperform at William Blair
William Blair analyst Matthew Phipps downgraded Tenax Therapeutics (TENX) to Market Perform from Outperform after the company announced that the Phase 3 LEVEL trial of oral levosimendan in patients wi...
Tenax Therapeutics price target lowered to $5 from $30 at Roth Capital
Roth Capital lowered the firm’s price target on Tenax Therapeutics (TENX) to $5 from $30 and keeps a Buy rating on the shares. Tenax’s Phase 3 LEVEL trial failed its…
Tenax Therapeutics Transcript: Study result
The phase III LEVEL trial in PH-HFpEF did not meet its primary endpoint, but levosimendan showed robust biomarker and hemodynamic improvements and a significant functional benefit in sicker patients with lower baseline walk distance. Future trials will focus on this responder population to maximize clinical impact.
Tenax Therapeutics Slides: Study result
Tenax Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
Tenax Therapeutics Press release: Study result
Tenax Therapeutics issued a press release on August 10, 2026, disclosing material business information to investors.
Tenax Therapeutics reports LEVEL trial did not meet primary endpoint
Tenax Therapeutics (TENX) announced topline results from the Phase 3 LEVEL clinical trial evaluating TNX-103 in patients with PH-HFpEF. LEVEL did not meet its primary endpoint of improvement in the…
Tenax Therapeutics' heart drug misses main goal in study, shares plunge
Tenax Therapeutics said on Monday its experimental heart drug failed to meet the main goal of a late-stage study.
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo
Tenax Therapeutics Earnings release: Q2 2026
Tenax Therapeutics released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
Tenax Therapeutics Quarterly report: Q2 2026
Tenax Therapeutics has published its Q2 2026 quarterly earnings report on July 31, 2026.
Tenax Therapeutics reports Q2 EPS (35c), consensus (36c)
“We are approaching an exciting moment, one for which we have been preparing since we began developing a therapy uniquely suited for PH-HFpEF. As we announced at the start of…